Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces acute lung injury in endotoxemic rats*
- 1 October 2005
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 33 (10) , 2309-2316
- https://doi.org/10.1097/01.ccm.0000183161.81503.7d
Abstract
Rosiglitazone, a potent agonist of peroxisome proliferator-activated receptor (PPAR)-gamma, exerts anti-inflammatory effects in vitro and in vivo. This study was designated to determine the effects of rosiglitazone on endotoxin-induced acute lung injury in rats. Prospective, experimental study. University research laboratory. Thirty-six male Wistar rats. All the animals were randomly assigned to one of six groups (n = 6 per group) and were given either lipopolysaccharide (6 mg/kg intravenously) or saline, pretreated with rosiglitazone (0.3 mg/kg intravenously) or vehicle (10% dimethyl sulphoxide) 30 mins before lipopolysaccharide. The selective PPAR-gamma antagonist GW9662 (0.3 mg/kg intravenously) or its vehicle (10% dimethyl sulphoxide) was given 20 mins before rosiglitazone. Endotoxemia for 4 hrs induced evident lung histologic injury and edema, both of which were significantly attenuated by rosiglitazone pretreatment. The protective effects of rosiglitazone were correlated with the reduction by 71% of the increase of myeloperoxidase activity and the reduction by 84% of the increase of malondialdehyde in the lung tissue. The pulmonary hyperproduction of nitric oxide was reduced by 82% of the increase related to lipopolysaccharide challenge. Pretreatment with rosiglitazone also markedly suppressed lipopolysaccharide-induced expression of inducible nitric oxide synthase messenger RNA and protein in the lung, as demonstrated by reverse transcription-polymerase chain reaction or Western blot analysis. Immunohistochemical analysis revealed that rosiglitazone inhibited the formation of nitrotyrosine, a marker for peroxynitrite reactivity, in the lung tissue. In addition, the specific PPAR-gamma antagonist GW9662 antagonized the effects of rosiglitazone. This study provides evidence, for the first time, that the PPAR-gamma agonist rosiglitazone significantly reduces endotoxin-induced acute lung injury in rats.Keywords
This publication has 39 references indexed in Scilit:
- Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2on bleomycin-induced lung injuryEuropean Respiratory Journal, 2005
- Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathwayKidney International, 2004
- Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice*Critical Care Medicine, 2004
- Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndromeThe Journal of Pathology, 2003
- PPARγ-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNFα secretion is not mediated by PTEN regulationBiochemical and Biophysical Research Communications, 2003
- In vivo lipid‐derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDSThe FASEB Journal, 2002
- Peroxynitrite Is an Essential Component of Cytokines Production Mechanism in Human Monocytes through Modulation of Nuclear Factor-κB DNA Binding ActivityJournal of Biological Chemistry, 2002
- Relative Contribution of Hemopoietic and Pulmonary Parenchymal Cells to Lung Inducible Nitric Oxide Synthase (iNOS) Activity in Murine EndotoxemiaBiochemical and Biophysical Research Communications, 2001
- Oxidized Low Density Lipoprotein Inhibits Interleukin-12 Production in Lipopolysaccharide-activated Mouse Macrophages via Direct Interactions between Peroxisome Proliferator-activated Receptor-γ and Nuclear Factor-κBJournal of Biological Chemistry, 2000
- Endotoxin-induced organ injuryCritical Care Medicine, 1993